Project Grant R37CA300137
Award Date 6/2/26
Completion Date 5/31/31
Dollars Obligated $748K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $731,503 Project Grant to Sloan-Kettering Institute for Cancer Research, effective June 1, 2026 through May 31, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial (RCT) evaluating Brief Behavioral Activation for Older Adult Cancer Survivors (BBA-OACS), a telehealth-based psychotherapy intervention designed to address clinically significant depression among...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $644,423 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 18, 2026, with a completion date of May 31, 2031. This award supports the development and evaluation of short-wave infrared (SWIR) Cerenkov luminescence imaging (CLI) technology to improve visualization and monitoring of targeted radiotherapy agents and diagnostic radiotracers. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $457,252 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 10, 2026, with a completion date of May 31, 2028. The award supports the development and implementation of RECONJOINT, a web-based decision support tool designed to improve shared decision-making for breast reconstruction surgery. The tool utilizes adaptive choice-based...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from April 1, 2026 through March 31, 2031. This project focuses on identifying and targeting tumor regenerative cells (TRCs) that drive treatment resistance and metastatic recurrence in locally advanced rectal cancer (LARC) patients undergoing total neoadjuvant therapy (TNT). Through...
- Federal Grant Award Summary The National Cancer Institute awarded a $444,590 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with completion targeted for May 31, 2028. The project focuses on evaluating genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms (MPNs), rare blood cancers with poor prognosis and limited effective...
- Summary of Federal Project Grant Award The National Cancer Institute awarded $807,644 to Sloan-Kettering Institute for Cancer Research on August 13, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and pilot DESCANSO, a culturally adapted cognitive behavioral therapy intervention targeting the symptom cluster of depression, insomnia, and fatigue in Spanish-speaking Latino cancer patients. The five-year project (completion date: July 31, 2030) will...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Miami a $2.75M Project Grant on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a four-year clinical research study examining the effects of remotely-delivered cognitive behavioral stress management (R-CBSM) on cancer-accelerated aging in distressed breast cancer survivors aged 50 and older. The study will enroll 192 breast cancer survivors who completed...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $676,849 to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to substantially enhance MIRDSOFT.org, an open-source radiation dosimetry platform. The award, effective July 1, 2026 through June 30, 2031, supports the development of enhanced dosimetry software and computational tools to enable personalized dose estimation in nuclear medicine and...